Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium

• Published in: European urology Vol. 86; no. 1; pp. 20 - 26
• Main Authors: Bjerner, Johan, Bratt, Ola, Aas, Kirsti, Albertsen, Peter C., Fosså, Sophie D., Kvåle, Rune, Lilja, Hans, Müller, Christoph, Müller, Stig, Stensvold, Andreas, Thomas, Owen, Røe, Oluf D., Vickers, Andrew, Walz, Jochen, Carlsson, Sigrid V., Oldenburg, Jan
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.07.2024
• Subjects: Adult; Aged; Cancer and Oncology; Cancer och onkologi; Clinical Medicine; Humans; Incidence; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; Nephrology; Njurmedicin; Norway - epidemiology; Predictive Value of Tests; Prostate cancer; Prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - mortality; Risk Assessment; Risk Factors; Screening; Norway; Screening; Prostate-specific antigen; Prostate cancer

Among 40- to 70-yr-old men with a “normal” prostate-specific antigen (PSA) value (below 4 ng/ml) sampled in routine medical care, the risk of dying from prostate cancer in the next two decades is associated with the PSA level. Prostate-specific antigen (PSA) levels in midlife are strongly associated...